Clinical trial
Trial of Memantine for Cognitive Impairment in Multiple Sclerosis
NCT00300716 · Oregon Health and Science University, Other · Completed
Key facts
| NCT number | NCT00300716 |
|---|---|
| Title | Trial of Memantine for Cognitive Impairment in Multiple Sclerosis |
| Official title | Double Blind Placebo Controlled Pilot Trial of Memantine for Cognitive Impairment in Multiple Sclerosis |
| Lead sponsor | Oregon Health and Science University, Other |
| Collaborators | Forest Laboratories Industry University of Southern California University of Texas Southwestern Medical Center MS-Hub Seattle |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Sclerosis, Cognition Disorders |
| Intervention type | Drug |
| Interventions | Memantine |
| Enrollment | 82 |
| Start date | Apr 1, 2004 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Mar 9, 2006 |
| Last update posted | Oct 15, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: